Treatment of transthyretin amyloidosis using diflunisal

Treatment of transthyretin amyloidosis using diflunisal - Treatment of TTR amyloidosis using diflunisal

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007508

Enrollment

Registered

2012-03-31

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

transthyretin amyloidosis

Interventions

Orally administration of diflunisal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: histologically proved TTR amyloidosis patients

Exclusion criteria

Exclusion criteria: renal dysfunction pregnancy lactation

Design outcomes

Primary

Measure	Time frame
Clinical FAP scale	—

Secondary

Measure	Time frame
Cardiac wall thickness serum BNP level	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026